Copper aspirinate use of copper aspirinate as a pigment in PVC and Polystyrene has also been investigated. Copper aspirinate Copper(II) aspirinate is an aspirin chelate of copper(II) cations (Cu). It is used to treat rheumatoid arthritis. Copper aspirinate can be prepared by several methods. In one route of preparation, an excess of acetylsalicylic acid is dissolved in aqueous sodium carbonate. Sodium hydroxide is not suitable for this purpose, because it will hydrolyse acetylsalicylic acid ("ASA") into salicylic acid and sodium acetate. The resulting solution is then filtered to remove any undissolved acetylsalicylic acid and is mixed with a solution containing Cu cations
4-Aminosalicylic acid enzymatic activity. PAS was first synthesized by Seidel and Bittner in 1902. It was rediscovered by the Swedish chemist Jörgen Lehmann upon the report that the tuberculosis bacterium avidly metabolized salicylic acid. Lehmann first tried PAS as an oral TB therapy late in 1944. The first patient made a dramatic recovery. The drug proved better than streptomycin, which had nerve toxicity and to which TB could easily develop resistance. In the 1948, researchers at Britain's Medical Research Council demonstrated that combined treatment with streptomycin and PAS was superior to either drug alone, and established the principle of combination therapy for